A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
Autorzy:
de Braud F; Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Oncology Department, University of Milan, via G. Venezian, 1, 20133 Milan, Italy. Machiels JH; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, Belgium. Boggiani D; Medical Oncology Unit, University Hospital of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy. Rottey SWH; Drug Research Unit Ghent, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium. Duca M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, Italy. Laruelle M; Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, Belgium. Salvagni S; Policlinico S. Orsola Malphigi, via Giuseppe Massarenti, 13, 40138 Bologna, Italy. Damian S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, Italy. Lapeire LDF; Drug Research Unit Ghent, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium. Tiseo M; Medical Oncology Unit, University Hospital of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy. Dermine A; Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université catholique de Louvain, Avenue Hippocrate 10, 200 Woluwe-Saint-Lambert, 1200 Brussels, Belgium. Ould-Kaci M; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd, Ridgefield, CT 06877, USA. Braunger J; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, Germany. Rascher J; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, Germany. Fischer D; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riß, Germany. Hoefler J; Staburo GmbH, Aschauer Str. 26b, 81549 Munich, Germany, on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. MarianiGL; Boehringer Ingelheim, via Giovanni Lorenzini, 8, 20139 Milan, Italy. Cresta S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian, 1, 20133 Milan, Italy.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 May 31; Vol. 12 (6). Date of Electronic Publication: 2020 May 31.
Early hypophosphatemia in preterm infants receiving aggressive parenteral nutrition.
Autorzy:
Brener Dik PH; Division of Neonatology, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Galletti MF; Division of Neonatology, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Fernández Jonusas SA; Division of Neonatology, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Alonso G; Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. MarianiGL; Division of Neonatology, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Fustiñana CA; Division of Neonatology, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
